Neurotech International (Australia) Today
| NTI Stock | 0.07 0 1.45% |
Performance1 of 100
| Odds Of DistressOver 65
|
Neurotech International is selling for under 0.07 as of the 30th of November 2024; that is 1.45 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.065. Neurotech International has more than 65 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Neurotech International are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | Category Healthcare | Classification Health Care |
Neurotech International is entity of Australia. It is traded as Stock on AU exchange. The company has 1.03 B outstanding shares. More on Neurotech International
Moving against Neurotech Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Neurotech Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Neurotech International's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Neurotech International or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | IT (View all Themes) | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, IT, Health Care, Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Computing (View all Sectors) | ||||
Neurotech International's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Neurotech International's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsNeurotech International can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neurotech International's financial leverage. It provides some insight into what part of Neurotech International's total assets is financed by creditors.
| |||||
Neurotech International (NTI) is traded on Australian Securities Exchange in Australia and employs 9 people. Neurotech International is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 72.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurotech International's market, we take the total number of its shares issued and multiply it by Neurotech International's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Neurotech International operates under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 1.03 B outstanding shares.
Neurotech International generates negative cash flow from operations
Check Neurotech International Probability Of Bankruptcy
Ownership AllocationNeurotech International maintains a total of 1.03 Billion outstanding shares. Neurotech International holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Neurotech Ownership Details
Neurotech International Risk Profiles
Although Neurotech International's alpha and beta are two of the key measurements used to evaluate Neurotech International's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.54 | |||
| Semi Deviation | 3.61 | |||
| Standard Deviation | 3.76 | |||
| Variance | 14.12 |
Neurotech Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Neurotech International without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Neurotech International Corporate Management
Elected by the shareholders, the Neurotech International's board of directors comprises two types of representatives: Neurotech International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurotech. The board's role is to monitor Neurotech International's management team and ensure that shareholders' interests are well served. Neurotech International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurotech International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emanuela Russo | Chief Board | Profile | |
| Alessandra Gauvin | Joint Secretary | Profile | |
| Alexandra Andrews | Chief Officer | Profile | |
| Peter BSc | Chief Ltd | Profile | |
| Associate Ellaway | Chief Officer | Profile | |
| ACIS ACIS | Company Sec | Profile |
Additional Tools for Neurotech Stock Analysis
When running Neurotech International's price analysis, check to measure Neurotech International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurotech International is operating at the current time. Most of Neurotech International's value examination focuses on studying past and present price action to predict the probability of Neurotech International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurotech International's price. Additionally, you may evaluate how the addition of Neurotech International to your portfolios can decrease your overall portfolio volatility.